Articles Posted in Mass Torts

Published on:

A new study published in the Journal of Investigative Dermatology has raised alarms about the safety of popular acne products, many of which have been found to contain high levels of benzene, a known carcinogen. The findings highlight a significant health risk associated with these products, particularly as they are frequently used by teenagers and young adults. This is the second major analysis to reveal the presence of benzene in acne creams and cleansers, and it confirms concerns initially brought up by researchers earlier this year.

The Study and its Findings

Researchers tested over 100 benzoyl peroxide (BPO) acne products sold in major retailers across six states, uncovering that about one-third of these products were contaminated with benzene. Notably, products like Proactiv and CVS-brand face wash were found to contain benzene levels that far exceed the safety limits set by the FDA. Proactiv was found to have 18 times—18 times!— the amount of benzene allowed in U.S. drugs, while a CVS-brand face wash had 13 times the acceptable level. Such findings have led to increased calls for regulatory action and lawsuits to address this potential public health hazard.

Published on:

This page is about Veozah lawsuits for victims who have suffered a liver injury.

Veozah, a medication commonly used by women to alleviate hot flashes during menopause, has recently been linked to reports of serious liver injuries. Many women have turned to Veozah. It is, everyone seems to agree, an effective solution for many managing the uncomfortable symptoms of menopause, such as sudden sweating, intense heat, and rapid heartbeat that disrupt daily life. Yet, despite its effectiveness in reducing these symptoms, emerging evidence suggests that Veozah may pose a risk to liver health, leading to potentially severe complications.

Understanding Veozah and Its Use

Published on:

If you or a loved one experienced pain, discomfort, or complications after receiving a BioZorb implant following breast cancer surgery, you are not alone. Across the United States, patients are taking legal action to hold the manufacturer, Hologic, accountable for the harm caused by this device.

The BioZorb implant, manufactured by Hologic, Inc., is a class II medical device first cleared by the FDA in 2012 under the 510(k) process. It is an implantable radiographic marker composed of a bioabsorbable material (polylactic acid) and six titanium radiopaque clips, which are designed to mark soft tissue sites during radiation therapy following breast cancer surgery. The device is intended to provide a three-dimensional marker for more precise radiation targeting while gradually dissolving in the body over time.

BioZorb works. But it has also been linked to several complications, including prolonged pain, discomfort, infection, device migration, and non-absorption. Many patients have reported the formation of hardened masses, scar tissue, and additional injuries at the implant site. The device has also been associated with increased radiation exposure and adverse reactions requiring further surgeries for removal.

Published on:

The Fosamax lawsuit suffered a long and slow death.  The plaintiffs did not deserve this long and awful ride.  But the litigation over a decade later appears to be (nearly) dead. This post was first written in 2013 and has been updated in 2023 and 2024.

September 2024 Foxamax Lawsuit Update

In a ruling that revives these lawsuits, the Third Circuit ruled that the FDA letter denying Merck’s proposed labeling changes for its osteoporosis drug, Fosamax, does not amount to a final agency action that preempts state law “failure to warn” claims. The decision centers on over 500 plaintiffs who allege that Merck failed to provide adequate warnings about the risk of atypical femoral fractures associated with the drug. The court concluded that the New Jersey federal judge wrongly prioritized FDA informal communications over the plaintiffs’ arguments against preemption.

Published on:

Snapchat, the popular social media platform operated by Snap Inc., has faced a series of Snapchat lawsuits in recent years alleging that its design features and inadequate safety measures have made it a breeding ground for “sextortion” and other forms of extortion and exploitation, particularly targeting minors. These legal actions have highlighted significant concerns parents have about this app’s responsibility to protect its young users from predators who misuse its features. The consequences when this happens can be tragic.

Snapchat

Snapchat, launched in 2011, quickly gained popularity, especially among younger demographics, for its unique features, such as disappearing messages, which kids love for obvious reasons, and multimedia sharing.